Review for 'Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: a subgroup analysis of the randomized <scp>CAROLINA</scp> trial'

Subjects

Subjects :

medicine.medical_specialty
business.industry
Subgroup analysis
Dipeptidyl peptidase-4 inhibitor
Type 2 diabetes
Linagliptin
medicine.disease
Glimepiride
Internal medicine
medicine
Older people
business
Cardiovascular outcomes
medicine.drug

Details

Database :

OpenAIRE

Accession number :

edsair.doi.dedup.....1940344f3e5cfd3e75caf7e9ae9d3005

Full Text :

https://doi.org/10.1111/dom.14254/v1/review6